Clinical bottom line
Pediatric acute dystonia and extrapyramidal reactions (EPRs) are potentially distressing and sometimes emergent adverse effects primarily associated with dopamine antagonist medications such as metoclopramide, haloperidol, and risperidone. Prompt recognition and treatment in emergency settings are critical to relieve symptoms and prevent complications. Evidence supports the use of anticholinergic agents (e.g., benztropine, diphenhydramine) and benzodiazepines as first-line therapies, with careful consideration of causative agents and patient-specific factors. Awareness of drug-induced risk profiles and early intervention can improve outcomes and reduce unnecessary investigations.
What the evidence shows
Acute dystonia in children often presents with involuntary muscle contractions, oculogyric crises, torticollis, and laryngospasm, which can be alarming and mimic other neurological emergencies. Kanburoglu et al. (2013) emphasize that acute dystonia can be a true emergency requiring rapid diagnosis and treatment to prevent airway compromise and distress. The majority of cases are linked to dopamine receptor antagonists, including antiemetics like metoclopramide and antipsychotics such as haloperidol and risperidone (Reactions Weekly 2018, 2019).
Metoclopramide-induced dystonia remains a notable concern in pediatrics, with Reactions Weekly (2019) documenting multiple cases highlighting the need for cautious use and monitoring. Similarly, haloperidol and risperidone have been implicated in extrapyramidal side effects, with Reactions Weekly (2018) reporting on their risk profiles and management strategies.
Treatment evidence favors anticholinergic agents to reverse dystonic reactions effectively. Diphenhydramine and benztropine are commonly used, though direct pediatric randomized controlled trials are limited. Benzodiazepines, such as diazepam, have also been employed, especially when anticholinergics are contraindicated or insufficient (Reactions Weekly 2023). The rapid onset of symptom relief following administration supports their clinical utility.
Other atypical antipsychotics (amisulpride, olanzapine, quetiapine, aripiprazole) have been associated with extrapyramidal symptoms, albeit less frequently, and warrant vigilance (Reactions Weekly 2019, 2021). Polypharmacy increases the risk of dystonia and EPRs, underscoring the importance of medication review in affected patients (Reactions Weekly 2017).
Caveats and uncertainty
The evidence base for pediatric acute dystonia management is largely derived from case reports, pharmacovigilance data, and expert consensus rather than large randomized trials, limiting the strength of recommendations. Variability in presentation and severity complicates diagnosis, and dystonia can be mistaken for seizures or other neurological disorders, potentially delaying treatment (Kanburoglu et al., 2013).
There is limited data on optimal dosing, timing, and choice of anticholinergic versus benzodiazepine therapy in children, and adverse effects of these treatments themselves require consideration. Additionally, the risk-benefit balance of continuing causative medications after an acute episode remains unclear and must be individualized.
Drug interactions and underlying neurological or metabolic conditions may influence susceptibility to dystonia and response to treatment, but these factors are incompletely characterized in the pediatric population.
How this may change practice
Emergency clinicians and pediatricians should maintain a high index of suspicion for acute dystonia and extrapyramidal reactions in children presenting with sudden abnormal movements or posturing, especially if recently exposed to dopamine antagonists. Early recognition and prompt administration of anticholinergic agents or benzodiazepines can rapidly alleviate symptoms and reduce distress.
Medication histories should be carefully reviewed to identify potential causative agents, and alternative therapies considered when feasible. Educating families about the signs of dystonia and the importance of timely medical evaluation may prevent delays in care.
Protocols for managing acute dystonia in pediatric emergency settings could be developed or updated to incorporate current evidence and expert recommendations, emphasizing rapid assessment, treatment, and follow-up.
Further research is needed to establish pediatric-specific guidelines on dosing, treatment sequencing, and long-term management after dystonic episodes.